1-4 of 4
Vernon K. Sondak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Open Access
Joseph Markowitz, Michael Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani, Christopher W. Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T. Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B. De Aquino, Vernon K. Sondak, Ahmad A. Tarhini, Youngchul Kim, Patricia Lawman, Shari Pilon-Thomas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (8): 1139–1143.
https://doi.org/10.1158/1535-7163.MCT-23-0652
Published: 01 August 2024
View articletitled, First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Open the PDF for First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0 in another window
Includes: Supplementary data
Journal Articles

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines

Free
Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, Keiran S.M. Smalley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 73–83.
https://doi.org/10.1158/1535-7163.MCT-17-0196
Published: 01 January 2018
View articletitled, Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines
Open the PDF for Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines in another window
Includes: Supplementary data
Journal Articles

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Free
Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodriguez-Lopez, Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 2793–2804.
https://doi.org/10.1158/1535-7163.MCT-14-0452
Published: 04 December 2014
View articletitled, Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Open the PDF for Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models in another window
Journal Articles

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

Free
H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen, Keiran S.M. Smalley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 901–912.
https://doi.org/10.1158/1535-7163.MCT-12-1003
Published: 09 June 2013
View articletitled, Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
Open the PDF for Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma in another window
Includes: Supplementary data